Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 69.96
BTX's Cash to Debt is ranked higher than
73% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. BTX: 69.96 )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 69.96

Equity to Asset 0.20
BTX's Equity to Asset is ranked higher than
53% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BTX: 0.20 )
BTX' s 10-Year Equity to Asset Range
Min: -45.87   Max: 0.99
Current: 0.2

-45.87
0.99
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
76% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -4.33
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1248.45
BTX's Operating margin (%) is ranked higher than
57% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. BTX: -1248.45 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -1248.45

-9788.46
-116.83
Net-margin (%) -865.49
BTX's Net-margin (%) is ranked higher than
58% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. BTX: -865.49 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -865.49

-9471.15
-137.48
ROE (%) -299.82
BTX's ROE (%) is ranked higher than
51% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. BTX: -299.82 )
BTX' s 10-Year ROE (%) Range
Min: -2802.7   Max: -49.44
Current: -299.82

-2802.7
-49.44
ROA (%) -84.83
BTX's ROA (%) is ranked higher than
56% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. BTX: -84.83 )
BTX' s 10-Year ROA (%) Range
Min: -624.96   Max: -33.33
Current: -84.83

-624.96
-33.33
ROC (Joel Greenblatt) (%) -2247.02
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. BTX: -2247.02 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21242.11   Max: -800
Current: -2247.02

-21242.11
-800
Revenue Growth (3Y)(%) -3.90
BTX's Revenue Growth (3Y)(%) is ranked higher than
75% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 128.9
Current: -3.9

0
128.9
EBITDA Growth (3Y)(%) 63.40
BTX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BTX: 63.40 )
BTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.9   Max: 63.9
Current: 63.4

-48.9
63.9
EPS Growth (3Y)(%) 42.50
BTX's EPS Growth (3Y)(%) is ranked higher than
95% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BTX: 42.50 )
BTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.6   Max: 67.1
Current: 42.5

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 36.20
BTX's P/B is ranked higher than
59% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. BTX: 36.20 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 36.2

5.65
83
P/S 40.20
BTX's P/S is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. BTX: 40.20 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 40.2

4.83
124
EV-to-EBIT -4.56
BTX's EV-to-EBIT is ranked higher than
69% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BTX: -4.56 )
BTX' s 10-Year EV-to-EBIT Range
Min: -71.7   Max: -1.1
Current: -4.56

-71.7
-1.1
Current Ratio 1.72
BTX's Current Ratio is ranked higher than
58% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. BTX: 1.72 )
BTX' s 10-Year Current Ratio Range
Min: 0.02   Max: 76
Current: 1.72

0.02
76
Quick Ratio 1.67
BTX's Quick Ratio is ranked higher than
60% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BTX: 1.67 )
BTX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 74
Current: 1.67

0.02
74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.10
BTX's Price/Median PS Value is ranked higher than
85% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. BTX: 1.10 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 15.74
Current: 1.1

0.14
15.74
Earnings Yield (Greenblatt) -20.10
BTX's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. BTX: -20.10 )
BTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -20.1   Max: 0
Current: -20.1

-20.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 15 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 04 2014
BioTime to Present at the LD Micro VII Conference Dec 03 2014
BIOTIME INC Financials Nov 15 2014
BIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
BioTime Reports Third Quarter Results and Recent Progress Nov 10 2014
BIOTIME INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK